Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

ClinicalTrials.gov ID: NCT03917472

Public ClinicalTrials.gov record NCT03917472. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KINGFISHER)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study was to evaluate the efficacy and safety of brolucizumab vs. aflibercept in the treatment of patients with visual impairment due to diabetic macular edema (DME).

Study identification

NCT ID
NCT03917472
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
517 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 16, 2019
Primary completion
Mar 23, 2021
Completion
Mar 23, 2021
Last update posted
Aug 11, 2022

2019 – 2021

United States locations

U.S. sites
74
U.S. states
26
U.S. cities
69
Facility City State ZIP Site status
Novartis Investigative Site Phoenix Arizona 85016
Novartis Investigative Site Phoenix Arizona 85053
Novartis Investigative Site Tucson Arizona 85704-5614
Novartis Investigative Site Beverly Hills California 90211
Novartis Investigative Site Campbell California 95008
Novartis Investigative Site Fresno California 93720
Novartis Investigative Site Huntington Beach California 92647
Novartis Investigative Site Loma Linda California 92354
Novartis Investigative Site Mountain View California 94040
Novartis Investigative Site Oakland California 94609
Novartis Investigative Site Pasadena California 91107
Novartis Investigative Site Poway California 92064
Novartis Investigative Site Rancho Cordova California 95670
Novartis Investigative Site Redlands California 92374
Novartis Investigative Site Riverside California 92505
Novartis Investigative Site Sacramento California 95817
Novartis Investigative Site Sacramento California 95841
Novartis Investigative Site San Francisco California 94107
Novartis Investigative Site Santa Ana California 92705
Novartis Investigative Site Santa Barbara California 93103
Novartis Investigative Site Torrance California 90509-2910
Novartis Investigative Site Ventura California 93003
Novartis Investigative Site Altamonte Springs Florida 32701
Novartis Investigative Site Deerfield Beach Florida 33064
Novartis Investigative Site Fort Lauderdale Florida 33309
Novartis Investigative Site Fort Myers Florida 33912-7125
Novartis Investigative Site Orlando Florida 32804
Novartis Investigative Site Pinellas Park Florida 33782
Novartis Investigative Site St. Petersburg Florida 33711
Novartis Investigative Site Tampa Florida 33609
Novartis Investigative Site Atlanta Georgia 30342
Novartis Investigative Site Marietta Georgia 30060
Novartis Investigative Site ‘Aiea Hawaii 96701
Novartis Investigative Site Bloomington Illinois 61704
Novartis Investigative Site Oak Forest Illinois 60452
Novartis Investigative Site Springfield Illinois 62704
Novartis Investigative Site Indianapolis Indiana 46280
Novartis Investigative Site New Albany Indiana 47150
Novartis Investigative Site West Des Moines Iowa 50266
Novartis Investigative Site Leawood Kansas 66211
Novartis Investigative Site Lenexa Kansas 66215
Novartis Investigative Site Hagerstown Maryland 21740
Novartis Investigative Site Boston Massachusetts 02114
Novartis Investigative Site Royal Oak Michigan 48073
Novartis Investigative Site Minneapolis Minnesota 55435
Novartis Investigative Site Kansas City Missouri 64133
Novartis Investigative Site Reno Nevada 89502
Novartis Investigative Site Bloomfield New Jersey 07003
Novartis Investigative Site Teaneck New Jersey 07666
Novartis Investigative Site Rochester New York 14620
Novartis Investigative Site Hickory North Carolina 28602
Novartis Investigative Site Southern Pines North Carolina 28387
Novartis Investigative Site Cleveland Ohio 44122
Novartis Investigative Site Columbus Ohio 43210
Novartis Investigative Site Dublin Ohio 43016
Novartis Investigative Site Eugene Oregon 97401
Novartis Investigative Site Kingston Pennsylvania 95403
Novartis Investigative Site Chattanooga Tennessee 37421
Novartis Investigative Site Germantown Tennessee 38138
Novartis Investigative Site Abilene Texas 79606
Novartis Investigative Site Austin Texas 78705
Novartis Investigative Site Austin Texas 78731
Novartis Investigative Site Austin Texas 78750
Novartis Investigative Site Bellaire Texas 77401
Novartis Investigative Site Dallas Texas 75231
Novartis Investigative Site Fort Worth Texas 76104
Novartis Investigative Site Harlingen Texas 78550
Novartis Investigative Site Houston Texas 77025
Novartis Investigative Site Houston Texas 77030
Novartis Investigative Site San Antonio Texas 78240
Novartis Investigative Site Southlake Texas 76092
Novartis Investigative Site Norfolk Virginia 23502
Novartis Investigative Site Morgantown West Virginia 26506
Novartis Investigative Site Madison Wisconsin 53705-3611

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03917472, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 11, 2022 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03917472 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →